PULMONARY ANTIHYPERTENSIVES PRIOR AUTHORIZATION REQUEST FORM

OptumRx
P.O. Box 25184
Santa Ana, CA, 92799
Phone: (800) 310-6826 Fax: (866) 940-7328

Optum Rx®

United Healthcare Community Plan

Today's Date
☐☐ / ☐☐ / ☐☐☐☐

Note: This form must be completed by the prescribing provider.

****All sections must be completed or the request will be returned****

Patient's Medicaid # ☐☐☐☐☐☐☐☐☐☐☐☐	Date of Birth ☐☐ / ☐☐ / ☐☐☐☐
Patient's Name	Prescriber's Name
Prescriber's IN License # ☐☐☐☐☐☐☐☐	Specialty
Prescriber's NPI # ☐☐☐☐☐☐☐☐☐☐☐☐	Prescriber's Signature
Return Fax # ☐☐☐ - ☐☐☐ - ☐☐☐☐	Return Phone # ☐☐☐ - ☐☐☐ - ☐☐☐☐
Check box if requesting retro-active PA ☐	Date(s) of service requested for retro-active eligibility (if applicable):

Note: Submit PA requests for retroactive claims (dates of service prior to eligibility determination, but within established eligibility timelines) with dates of service prior to 30 calendar days of submission separately from current PA requests (dates of service 30 calendar days or less and going forward).

Requested Medication	Strength	Quantity	Dosage Regimen

General information applicable to all products:

Pulmonary Antihypertensive PA Requirements for ALL agents:

1. Member has a diagnosis of pulmonary arterial hypertension ☐ Yes ☐ No
2. Member has a diagnosis of pulmonary hypertension associated with interstitial lung disease (only applicable to Tyvaso/Tyvaso DPI) ☐ Yes ☐ No
3. Member has a diagnosis of chronic thromboembolic pulmonary hypertension (CTEPH) (only applicable to Adempas) ☐ Yes ☐ No
4. Requested agent has been prescribed by, or in consultation with, a pulmonologist or cardiologist ☐ Yes ☐ No

Product specific information:

If the request is for Adempas (riociguat):

1. For those of childbearing potential, a negative pregnancy test obtained in the past 30 days has been submitted ☐ Yes ☐ No ☐ Not applicable to member
   Date of negative pregnancy test (include documentation): _____
2. Member is currently receiving one of the following: nitrate therapy, PDE5 inhibitor, nonspecific PDE inhibitor (dipyridamole; theophylline; aminophylline), vericiguat ☐ Yes ☐ No
3. Member is enrolled in the riociguat REMS program if meeting eligibility requirement ☐ Yes ☐ No ☐ Not applicable to member
4. Dose requested is 7.5mg per day or less ☐ Yes ☐ No

   If no, please explain:_____

If the request is for Adcirca (tadalafil):

1. Member is currently receiving one of the following: nitrate therapy, PDE-5 inhibitor (other than the one being requested), riociguat ☐ Yes ☐ No
2. Dose requested is 40 mg per day or less ☐ Yes ☐ No

Note: 'Alyq' requires trial and failure of generic tadalafil or medical justification for use

If the request is for Letairis (ambrisentan):

1. Member is enrolled in the ambrisentan or PS-ambrisentan REMS program if meeting eligibility requirement ☐ Yes ☐ No ☐ Not applicable to member
2. For those of childbearing potential, a negative pregnancy test obtained in the past 30 days has been submitted ☐ Yes ☐ No ☐ Not applicable to member
   Date of negative pregnancy test (include documentation): _____
3. Member is currently receiving cyclosporine therapy (requires dose reduction) ☐ Yes ☐ No
   Note: dose of Letairis (ambrisentan) must be adjusted to max: 5 mg/day
4. Member has had a previous trial and failure of Tracleer (bosentan) ☐ Yes ☐ No
   If no, please explain_____
5. Dose requested is 10 mg per day or less ☐ Yes ☐ No

If the request is for Liqrev (sildenafil) oral suspension:

1. Member is 18 years of age or older ☐ Yes ☐ No
2. Member is unable to swallow tablet formulation ☐ Yes ☐ No
3. Member is currently receiving one of the following: nitrate therapy, riociguat, atazanavir, darunavir, fosamprenavir, indinavir, lopinavir/ritonavir, nelfinavir, ritonavir, saquinavir, tipranavir, PDE-5 inhibitor (other than the one being requested) ☐ Yes ☐ No
4. Dose requested is 60 mg per day or less ☐ Yes ☐ No
5. Member has had a previous trial and failure of sildenafil suspension ☐ Yes ☐ No
   If no, please explain_____

If the request is for Opsumit (macitentan):

1. Member is enrolled in the macitentan REMS program if meeting eligibility requirement
   ☐ Yes ☐ No ☐ Not applicable to member
2. For those of childbearing potential, a negative pregnancy test obtained in the past 30 days has been submitted ☐ Yes ☐ No ☐ Not applicable to member
   Date of negative pregnancy test (include documentation): _____
3. Member has had a previous trial and failure of Tracleer (bosentan) ☐ Yes ☐ No
   If no, please explain_____
4. Dose requested is 10 mg per day or less ☐ Yes ☐ No

If the request is for Opsynvi (macitentan/tadalafil):

1. Member is enrolled in the macitentan/tadalafil REMS program if meeting eligibility requirement
   ☐ Yes ☐ No ☐ Not applicable to member
2. For those of childbearing potential, a negative pregnancy test obtained in the past 30 days has been submitted ☐ Yes ☐ No ☐ Not applicable to member
   Date of negative pregnancy test (include documentation): _____
3. Member has had a previous trial and failure of separate components (macitentan & tadalafil)
   ☐ Yes ☐ No
   If no, please explain_____
4. Member is currently receiving one of the following: nitrate therapy, PDE-5 inhibitor (other than the one being requested), riociguat ☐ Yes ☐ No
5. Dose requested is 10 mg/40 mg per day or less ☐ Yes ☐ No

If the request is for Orenitram (treprostinil):

1. Does the member have severe hepatic impairment (Child-Pugh class C)? □ Yes □ No
   Note: members with Child-Pugh class C hepatic impairment will be denied; Orenitram titration packs will be limited to 1 pack per 90 days

If the request is for Revatio (sildenafil) tablets or injection:

1. Member is currently receiving one of the following: nitrate therapy, riociguat, atazanavir, darunavir, fosamprenavir, indinavir, lopinavir/ritonavir, nelfinavir, ritonavir, saquinavir, tipranavir, PDE-5 inhibitor (other than the one being requested) ☐ Yes ☐ No
2. Dose requested is 60 mg per day or less ☐ Yes ☐ No

If the request is for Revatio (sildenafil) oral suspension:

1. Member is under 12 years of age ☐ Yes ☐ No
2. Member is unable to swallow tablet formulation ☐ Yes ☐ No
3. Member is currently receiving one of the following: nitrate therapy, riociguat, atazanavir, darunavir, fosamprenavir, indinavir, lopinavir/ritonavir, nelfinavir, ritonavir, saquinavir, tipranavir, PDE-5 inhibitor (other than the one being requested) ☐ Yes ☐ No
4. Dose requested is 60 mg per day or less ☐ Yes ☐ No

If the request is for Tadliq (tadalafil) oral suspension:

1. Member is under 12 years of age ☐ Yes ☐ No
2. Member is unable to swallow tablet formulation ☐ Yes ☐ No
3. Member is currently receiving one of the following: nitrate therapy, PDE-5 inhibitor (other than the one being requested), riociguat ☐ Yes ☐ No
4. Dose requested is 40 mg per day or less ☐ Yes ☐ No
5. Member has had a previous trial and failure of sildenafil oral suspension ☐ Yes ☐ No

   If no, please explain_____

If the request is for Uptravi (selexipag):

1. Member has had a previous trial and failure of Orenitram (treprostinil) ☐ Yes ☐ No

   If no, please explain_____

2. Will the member be utilizing a CYP2C8 inhibitor (e.g., gemfibrozil) concurrently with selexipag? ☐ Yes ☐ No

   Note: members planning to use CYP2C8 inhibitors concurrently with selexipag will be denied

If the request is for Tracleer (bosentan):

Request is for:

☐ Tracleer tablet
☐ Tracleer dispersible tablet
☐ bosentan tablet*

1. Member is enrolled in the bosentan REMS program (***Note****: ALL members* ***must*** *be enrolled in the bosentan REMS program)* ☐ Yes ☐ No
2. For those of childbearing potential, a negative pregnancy test obtained in the past 30 days has been submitted ☐ Yes ☐ No ☐ Not applicable to member
   Date of negative pregnancy test (include documentation): _____
3. Will the member be utilizing cyclosporine-A or glyburide therapy concurrently with bosentan? ☐ Yes ☐ No

   Note: members planning to use cyclosporine-A or glyburide concurrently with bosentan will be denied

4. Member age: _____ weight: _____ LB/KG (circle one)
5. Does the requested dose exceed 250mg per day OR dose limits based on age/weight listed in criteria? ☐ Yes ☐ No

   If yes, please explain: _____

Note: Tracleer tablets are brand preferred. Authorization for generic bosentan tablets is contingent upon medical necessity for use instead of the branded agent.

If the request is for Winrevair (sotarcept-csrk)

1. Member is 18 years of age or older ☐ Yes ☐ No ☐
2. Member has had a previous trial and failure of at least 60 days of therapy with any agent from TWO of the following subcategories: endothelin receptor antagonists, phosphodiesterase 5-inhibitors, prostacyclin receptor modulators, or soluble guanylate cyclase inhibitor ☐ Yes ☐ No

   If yes, please list each agent and dates of trial (start and stop dates, if therapy is ongoing indicate as such):
   - Endothelin receptor antagonist:
     - Medication name: _____
     - Dates of trial:_____
   - Phosphodiesterase 5-inhibitor:
     - Medication name: _____
     - Dates of trial:_____
   - Prostacyclin receptor modulator:
     - Medication name: _____
     - Dates of trial:_____
   - Soluble guanylate cyclase inhibitor:
     - Medication name: _____
     - Dates of trial:_____

   If no, please explain_____
3. Member's actual body weight: _____ LB/KG (circle one)
   a. Does the requested dose exceed 0.7 mg/kg every 3 weeks? ☐ Yes ☐ No

      If yes, please explain:

      _____
4. Prescriber attests to all of the following:
   a. Prescriber has obtained baseline hemoglobin and platelet count prior to initiating therapy ☐ Yes ☐ No
   b. Baseline platelet count is 50,000/mm^3 (50 x 10^6/L) or greater ☐ Yes ☐ No
   c. Prescriber will continue to monitor hemoglobin and platelet count and adjust dosing per the prescribing information ☐ Yes ☐ No

CONFIDENTIAL INFORMATION

This facsimile transmission (and attachments) may contain protected health information from the Indiana Health Coverage Programs (IHCP), which is intended only for the use of the individual or entity named in this transmission sheet. Any unintended recipient is hereby notified that the information is privileged and confidential, and any use, disclosure, or reproduction of this information is prohibited.